formulari win set belbuca tailwind
invest summari reiter overweight rate
pt share belbuca continu grow meaning
good formulari win compani continu drive growth
year beyond first nine week belbuca rx track
first nine week addit coverag becom effect
forecast net sale growth belbuca believ
may end conserv base current rx trend increas access
price increas januari given buprenorphin less-addict properti
schedul ii opioid expect belbuca continu benefit increas
access beyond
posit quarter announc secur prefer
coverag belbuca neutral effect march effect
jan unit healthcar ow remov step edit belbuca
/caremark cover procarerx move belbuca
prefer posit addit belbuca butran ad
ohio worker comp formulari prefer medic effect
belbuca prescript grew vs continu grow
scott plesha appoint role presid cash
equival total fund oper
manag note call could potenti qualifi
addit tranch loan agreement lever compani
decreas cash burn extend cash runway includ better-than-
expect sale lower sg spend potenti partnership
divest compani product
report ep factset consensu
estim miss driven one-tim payment opioid associ
compani exceed consensu revenu estim
updat model decreas ep estim driven
reduct forecast mileston partial off-set increas
belbuca revenu estim
 valuat use blend dcf multipl ev/ebitda analysi
reach price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi reach price target
sever potenti downsid risk posit invest thesi price
sale earn may fail meet expect due varieti factor increas
competit declin demand higher cost reimburs issu
commerci landscap popul mani opioid pain therapi standard
formul abuse-deterr one
in-hous manufactur use third-parti manufactur produc
product addit manufactur reli third-parti supplier interrupt
facil supplier would materi effect commerci
bunavail belbuca
complianc issu product recal mandat regulatori author could
materi affect chang current assumpt legal risk could lead addit
liabil revenu loss fda could request compani remov product
market risk benefit analysi prove unfavor
sever right patent technolog compound
assur patent subject challeng
market bdsi stock volatil
appar cash runway may need seek addit fund order
adequ fund oper
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
exhibit bull bear base case scenario analysi
bdsisourc cantor fitzgerald research compani casebelbuca bunavail sale better expect addit partnership belbucamargin improv better expectedoveral opioid market size scenario casebelbuca bunavail sale in-lin expectationsno addit partnership belbucamargin remain lineoveral opioid market size scenario casebelbuca bunavail sale expectationsno addit partnership belbucamargin compressoveral opioid market size scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot higher forecast belbuca bunavail revenu gross one time charg associ join opioid associ oper non oper pre-tax tax net averag dilut cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom new bunavailpartn divest releas buprenorphinecomm technologypat gener entri per gener entri per settlementsourc cantor fitzgerald research compani report exhibit incom statement analysi
million year end decemb oper share chang yoytot cantor fitzgerald research compani report exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb chang cantor fitzgerald research compani report exhibit annual sale analysi
cantor fitzgerald research compani reportsyear end decemb exhibit analysi
million year end decemb flow provid oper activ net chang work net cash provid oper flow invest activitiespurchas proce sale net cash net cash use invest flow financ activ repay issuanc long term dividend net cash use provid financ decreas increas cash foreign equival begin equival end cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb current current properti total sharehold equityaccount payabl accru current term debt stockhold total liabil stockhold cantor fitzgerald research compani report march
biodeliveri scienc specialti pharmaceut compani focus treatment opioid addict pain compani
commerci proprietari addict therapi bunavail belbuca chronic pain
